FDA Grants Priority Review to ARV-1801, Potential Antibiotic for Pulmonary Flares in CF Jan 30, 2020 07:00 am | Vanessa Pataia

https://cysticfibrosisnewstoday.com/2020/01/30/arrevus-arv-1801-named-fda-qualified-infectious-disease-product-to-treat-pulmonary-flares-in-cf/?utm_source=Cystic+Fibrosis&utm_campaign=0e9a466f99-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b075749015-0e9a466f99-72020733

FDA Grants Priority Review to ARV-1801, Potential Antibiotic for Pulmonary Flares in CF

Jan 30, 2020 07:00 am | Vanessa Pataia

Arrevus announced that the U.S. Food and Drug Administration (FDA) has given a form of priority review to ARV-1801 (sodium fusidate tablets), a potential oral treatment of pulmonary exacerbations in people with cystic fibrosis (CF). A clinical trial in patients is in planning stages, the company added in a press release. This designation came in the form of […] The post FDA Grants Priority Review to ARV-1801, Potential Antibiotic for Pulmonary Flares in CF appeared first on Cystic Fibrosis News Today.

Read More